Literature DB >> 34351910

The Δ40p53 isoform inhibits p53-dependent eRNA transcription and enables regulation by signal-specific transcription factors during p53 activation.

Cecilia B Levandowski1, Taylor Jones1, Margaret Gruca2,3, Sivapriya Ramamoorthy4, Robin D Dowell2,3, Dylan J Taatjes1.   

Abstract

The naturally occurring Δ40p53 isoform heterotetramerizes with wild-type p53 (WTp53) to regulate development, aging, and stress responses. How Δ40p53 alters WTp53 function remains enigmatic because their co-expression causes tetramer heterogeneity. We circumvented this issue with a well-tested strategy that expressed Δ40p53:WTp53 as a single transcript, ensuring a 2:2 tetramer stoichiometry. Human MCF10A cell lines expressing Δ40p53:WTp53, WTp53, or WTp53:WTp53 (as controls) from the native TP53 locus were examined with transcriptomics (precision nuclear run-on sequencing [PRO-seq] and RNA sequencing [RNA-seq]), metabolomics, and other methods. Δ40p53:WTp53 was transcriptionally active, and, although phenotypically similar to WTp53 under normal conditions, it failed to induce growth arrest upon Nutlin-induced p53 activation. This occurred via Δ40p53:WTp53-dependent inhibition of enhancer RNA (eRNA) transcription and subsequent failure to induce mRNA biogenesis, despite similar genomic occupancy to WTp53. A different stimulus (5-fluorouracil [5FU]) also showed Δ40p53:WTp53-specific changes in mRNA induction; however, other transcription factors (TFs; e.g., E2F2) could then drive the response, yielding similar outcomes vs. WTp53. Our results establish that Δ40p53 tempers WTp53 function to enable compensatory responses by other stimulus-specific TFs. Such modulation of WTp53 activity may be an essential physiological function for Δ40p53. Moreover, Δ40p53:WTp53 functional distinctions uncovered herein suggest an eRNA requirement for mRNA biogenesis and that human p53 evolved as a tetramer to support eRNA transcription.

Entities:  

Year:  2021        PMID: 34351910     DOI: 10.1371/journal.pbio.3001364

Source DB:  PubMed          Journal:  PLoS Biol        ISSN: 1544-9173            Impact factor:   8.029


  7 in total

1.  Cytoplasmic p53β Isoforms Are Associated with Worse Disease-Free Survival in Breast Cancer.

Authors:  Luiza Steffens Reinhardt; Kira Groen; Brianna C Morten; Jean-Christophe Bourdon; Kelly A Avery-Kiejda
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

2.  Suppression of p53 response by targeting p53-Mediator binding with a stapled peptide.

Authors:  Benjamin L Allen; Kim Quach; Taylor Jones; Cecilia B Levandowski; Christopher C Ebmeier; Jonathan D Rubin; Timothy Read; Robin D Dowell; Alanna Schepartz; Dylan J Taatjes
Journal:  Cell Rep       Date:  2022-04-05       Impact factor: 9.995

Review 3.  Enhancer RNAs (eRNAs) in Cancer: The Jacks of All Trades.

Authors:  Sara Napoli; Nicolas Munz; Francesca Guidetti; Francesco Bertoni
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

Review 4.  Adaptive homeostasis and the p53 isoform network.

Authors:  Sunali Mehta; Hamish Campbell; Catherine J Drummond; Kunyu Li; Kaisha Murray; Tania Slatter; Jean-Christophe Bourdon; Antony W Braithwaite
Journal:  EMBO Rep       Date:  2021-11-15       Impact factor: 8.807

5.  Protocol variations in run-on transcription dataset preparation produce detectable signatures in sequencing libraries.

Authors:  Samuel Hunter; Rutendo F Sigauke; Jacob T Stanley; Mary A Allen; Robin D Dowell
Journal:  BMC Genomics       Date:  2022-03-07       Impact factor: 3.969

6.  The Elephant Evolved p53 Isoforms that Escape MDM2-Mediated Repression and Cancer.

Authors:  Monikaben Padariya; Mia-Lyn Jooste; Ted Hupp; Robin Fåhraeus; Borek Vojtesek; Fritz Vollrath; Umesh Kalathiya; Konstantinos Karakostis
Journal:  Mol Biol Evol       Date:  2022-07-02       Impact factor: 8.800

7.  Systematic mutagenesis of TFIIH subunit p52/Tfb2 identifies residues required for XPB/Ssl2 subunit function and genetic interactions with TFB6.

Authors:  Jacob Bassett; Jenna K Rimel; Shrabani Basu; Pratik Basnet; Jie Luo; Krysta L Engel; Michael Nagel; Alexander Woyciehowsky; Christopher C Ebmeier; Craig D Kaplan; Dylan J Taatjes; Jeffrey A Ranish
Journal:  J Biol Chem       Date:  2022-08-28       Impact factor: 5.486

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.